Media and Communications

News

1999 News Releases

Monday, December 27, 1999
Teva pharmaceutical industries Ltd. to launch generic equivalent of cardizem cd in all dosage forms immediately

 December 27, 1999, Petach Tikva, Israel. Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced that it will immediately launch to Diltiazem Extended Release Capsules (once-a-day) in all dosage strengths. Diltiazem ER is the generic equivalent of Hoechst's Cardizem CD, which is indicated for the treatment of hypertension and angina. Sales for Cardizem CD in United States for the twelve months ended June 30th, 1999 exceeded $650 million. Earlier Biovail Corporation International (NYSE: TSE: BVF) received final approval from the FDA for the generic version Cardizem CD. Teva has exclu Read More »

Thursday, December 02, 1999
Teva Pharmaceutical Industries Ltd. signs letter of intent to acquire Novopharm Limited

 December 2, 1999, Petach Tikva, Israel. Teva Pharmaceutical Industries Ltd. -announced today that it has entered into a letter of intent to acquire Novopharm Ltd. from Dan Family Holdings Ltd. Teva had previously announced in mid-October that the parties were in advanced discussions regarding a transaction. The consideration for the contemplated transaction would consist of approximately 4.8 million ordinary shares of Teva, which would represent approximately 7% of Teva's outstanding share capital on a fully diluted basis. Novopharm, a privately held Canadian corporation, is one of the leadin Read More »

Tuesday, November 30, 1999
Teva Pharmaceutical Receives First FDA Approval Of Buproprion Tablets

Jerusalem, Israel, November 30, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it had received from the US Food and Drug Administration an approval to manufacture and market Buproprion Tablets (in two strengths, 75mg and 100mg). Teva USA will launch the product in the USA imminently. Buproprion is Teva's generic version of Glaxo Wellcome's anti-depressant drug Wellbutring, of which annual US sales are approximately $110 million. Teva views this approval as significant as it is the first approval for a generic version of this drug. Teva Pharmaceutical Industries Read More »

Monday, November 15, 1999
Teva Pharmaceutical Industries, Ltd. Responds To Israeli News Articles

Jerusalem, Israel, November 15, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) said today, in response to reports in the Israeli press, that in accordance with the consolidation that is taking place within the global pharmaceutical industry, the Company, as part of its normal course of doing business, is having various discussions with numerous parties in various geographical markets regarding possible cooperations and/or collaboration. One of these companies is Agis Industries Pharmaceuticals, one of Israel's largest pharmaceutical companies. At this time, these discussions are pre Read More »

Tuesday, November 09, 1999
Teva Pharmaceutical Industries Ltd. And H. Lundbeck A/S Form Strategic Alliance for the Co-development and European Marketing Rights of Two Parkinson's Disease Drugs

Jerusalem, Israel, November 9, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and H. Lundbeck A/S are pleased to announce that today they entered into a long term strategic alliance agreement for the co-development and marketing in Europe of two innovative products for the treatment of Parkinson's disease. Teva will retain exclusive marketing rights in the rest of the world, including North America, for these products. The first product covered by the agreement is TV 1203 currently in phase II clinical studies. TV 1203 is a pro drug of L-dopa - the most frequently used product for t Read More »

Monday, November 01, 1999
Teva Pharmaceutical Industries Ltd Reports 1999 Third Quarter And Nine Months Financial Results 1999 Third Quarter Net Income Up 43%, In-Market Sales Of Copaxone Increase 68 % vs. Third Quarter 1998 Declares Regular Quarterly Cash Dividend

 Jerusalem, Israel, November 1, 1999 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) today reported that net income for the third quarter ended September 30, 1999, rose 43% to $36.1 million, or $0.57 per ADR, as compared to $25.3 million, or $0.41 per ADR, reported for the third quarter of 1998. The 1999 figures are before a one time write off in respect of "acquired R&D" of $17.7 million, $0.28 per ADR, resulting from the Copley acquisition. Total sales for the 1999 third quarter rose 6% to $321.1 million, as compared to $303.3 million in the third quarter of 1998. An in Read More »

Tuesday, October 19, 1999
Teva Pharmaceutical confirms discussions to acquire Novopharm Ltd.

Jerusalem, Israel, October 19, 1999 - Teva Pharmaceutical Industries Ltd. announced today that it is in advanced discussions regarding the acquisition of Novopharm Ltd. by Teva in a transaction involving Teva shares as consideration. Novopharm is one of the leading generic companies in Canada with substantial generic operations also in the U.S and Hungary. Any such transaction would be subject to the completion of definitive documentation, regulatory approvals in Canada, the U.S. and Hungary and Israeli law requirements. Teva does not intend to issue any further comments on these discussions u Read More »

Thursday, September 30, 1999
Teva Pharmaceutical Industries Ltd. And Bio-Technology General Corp. Announce Strategic Alliance In The Development And Worldwide Commercialization Of Generic Biotechnology Products

Jerusalem, Israel, September 30, 1999 -- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Bio-Technology General Corp. (Nasdaq: BTGC) announced that they have entered into a strategic alliance that will focus on the development and global commercialization of several generic recombinant therapeutic products. The agreement provides for each of the two companies to capitalize on their particular strengths. BTG's primary role will be to develop and manufacture the products, and Teva will have exclusive marketing rights. The agreement calls for Teva to make payment to BTG of up to US $20 mil Read More »

Tuesday, September 14, 1999
Teva Pharmaceutical Industries Ltd. Announces Completion Of Tender Offer For Copley Pharmaceutical, Inc.

Jerusalem, Israel, September 14, 1999 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its indirect wholly owned subsidiary Caribou Merger Corporation has accepted for payment approximately 18,900,000 shares of common stock of Copley Pharmaceutical, Inc. (Nasdaq: CPLY), representing approximately 93.8 % of the outstanding shares of Copley Pharmaceutical, Inc. (including approximately 550,000 tendered by means of guaranteed delivery), at $11.00 per share in cash in accordance with its tender offer for all outstanding shares of Copley Pharmaceutical, Inc. Approximately 1 Read More »

Tuesday, August 10, 1999
Teva Pharmaceutical Industries Ltd. to acquire Copley Pharmaceutical, INC.

Strengthens Teva-USA's Leadership in the U.S. Generic Market Jerusalem, Israel and Canton, MA, August 10, 1999 - Teva Pharmaceutical Industries Ltd, (Nasdaq: TEVIY) and Copley Pharmaceutical, Inc. (Nasdaq: CPLY) announced today that Copley and Teva Pharmaceuticals USA, Inc., Teva's U.S. subsidiary, have executed a definitive merger agreement providing for the acquisition by Teva-USA of all the outstanding shares of Copley for $11.00 per share in cash. The transaction is valued at approximately $220 million. The merger agreement provides for a cash tender offer by Caribou Merger Corporation, a Read More »

​​​